Today's Rundown Celgene pays $101M to work with Vividion on hard-to-drug proteins Dermira dumps acne drug after phase 3 flubs Prime Minister Theresa May calls for U.K. to stay in EMA after Brexit Homology seeks $100M from IPO, reveals Novartis deal numbers Patient deaths, FDA hold cloud Unum’s $86M IPO bid Featured Story | | | Monday, March 5, 2018 Celgene has paid $101 million to collaborate with Vividion on the discovery of small molecules that hit hard-to-drug proteins. The four-year alliance tasks Vividion with discovering drugs that interact with the ubiquitin proteasome system cells used to break proteins apart. |
|
|
Top Stories Monday, March 5, 2018 After pulling the plug on its acne drug, olumacostat glasaretil, Dermira will refocus on its pipeline programs for atopic dermatitis and excessive sweating. Monday, March 5, 2018 Britain's prime minister has called for the U.K. to remain part of the European Medicines Agency (EMA) after Brexit. The proposal jibes with the wishes of the biopharma industry, but it remains to be seen whether the European Union is receptive to the idea. Monday, March 5, 2018 Just a few weeks after signing a big deal with Novartis—now confirmed to have included $35 million upfront and almost $1 billion in milestones—Homology Medicines has pushed ahead with plans for a $100 million IPO. Monday, March 5, 2018 Unum revealed more than its IPO goals in an SEC filing Friday: a clinical hold on, and two patient deaths in, a phase 1 trial in non-Hodgkin's lymphoma. | This week's sponsor is cobra:bio. | | | 1ml Long Syringe Line Now Available
In response to customer demand, Cobra has invested in an expansion of capabilities for batches up to 20k units. Today ~80% of the market for high value, low volume biologicals utilises the 1ml long format. More... |
Resources Sponsored by: Reprints Desk The competitive landscape in medical device R&D is tough. And simply investing in R&D is no guarantee for profitability. So how do you accelerate time-to-market? Sponsored by: MK&A There’s no magic bullet to successful access but insights from patient advocates and industry experts can help shape future strategies. Learn how in this webinar. Sign up now! Presented by: Box and USDM Life Sciences Learn how biopharma and medical device companies can now collaborate on, manage and distribute regulated clinical, lab and manufacturing content in Box. That means all of your content is standardized on a single content repository that meets regulatory and compliance standards, so you can eliminate inefficient silos, enable seamless collaboration and accelerate the validation process. Sponsored by: RBC Wealth Management Employee stock option trading & administration, Restricted stock transactions (Rule 144), Affiliated trading plans (10b5-1), Directed share plans, Equity comp plan administration — private to public Sponsored by: WCG Selecting the right sites to conduct your clinical trials will determine the success or failure of meeting your enrollment goals. Presented by: Covance Global clinical trials are the trend and gaining in popularity, but running a global trial is not a straightforward process. This white paper explores some of the challenges associated with global clinical trials and considerations for ensuring that the collected data comply with the trial's overall objectives. Presented by: Charles River Join us as we discuss how Charles River Celsis® helped Labor L+S AG validate a 7-day membrane filtration sterility test using existing protocols. Presented by: Catalent Learn how Catalent Biologics is paving the way for flexible biologics development and manufacturing through advanced technologies and fully integrated multi-product facility. Presented by: Catalent Download the eBook to get articles from various Elsevier journals highlighting developments in ADC technology. Presented by: Catalent Learn how cell development and process scale-up can be optimized for antibodies requiring additional processing. Sponsored by: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. Drug Approval, Manufacturing Quality & Regulation 2018 | Online BioBasics: Biotech for the Non-Scientist March 29-30, 2018 | Boston, MA Drug Development Boot Camp® 2018 November 14-15, 2018 | Boston, MA | Register and start preparing Today! | 